BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1

20246 citationsJournal Articlegold Open Access

Authors

Young-Seung Kim · STCube (United States)

Seung-Hoon Lee · STCube (United States)

Andrew H Park · STCube (United States)

Chunai Wu · STCube (United States)

Bong‐Ki Hong · STCube (United States)

Hyunjin Jung

Steven H. Lin · The University of Texas MD Anderson Cancer Center

Abstract

Together, these results confirm that the potential of BTN1A1 is a bona fide immune checkpoint and a viable immunotherapeutic target for the treatment of individuals with anti-PD-1/PD-L1 refractory or resistant disease, opening new avenues to improving survival outcomes for patients with a range of cancers.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Immune Cell Function and Interaction Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 12, Issue 3, pp. e008303-e008303

DOI: 10.1136/jitc-2023-008303

Field-Weighted Citation Impact: 1.70